| Name | Title | Contact Details |
|---|
USANA Health Sciences’ mission is to develop and provide the highest quality, science-based health products, distributed internationally through network marketing, creating a rewarding financial opportunity for our independent Associates, shareholders, and employees. We’ve got history. Not baggage. We’ve been around since 1992, so we’re experienced (we’ve heard that’s a plus). And we look great for our age. Plus, we have substance to go along with our great looks. We’ve got top-notch manufacturing facilities, our own scientists and research and development team, and the highest standards for our nutritional products. We have an award-winning compensation plan and award-winning products. We don’t like to brag, but we come pretty highly recommended. That’s because we got off on the right foot.
USAID is a Washington, DC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
To be Hansei is to reflect on the past, learn from mistakes, and commit to doing better in the future. To stop Hansei is to stop learning. Hansei Solutions helps behavioral healthcare facilities nationwide do it better, combining full-service revenue cycle management technology with a personal touch to forge lasting and strategic partnerships. Simply put, Hansei enables providers to collect more, save more, remain compliant, and make more informed decisions impacting their growth and bottom line.
Medvantage LLC is one of the leading companies in the Healthcare, Pharmaceuticals, & Biotech sector.
Ampio is an innovative drug discovery and development company combining scientific, regulatory, and business capabilities to efficiently develop a robust portfolio of novel therapeutic candidates. These therapeutic candidates, if approved, will address significant inflammatory conditions for which limited treatment options exist. Ampio’s therapeutic product pipeline has been developed through more than two decades of study at leading hospital-based research centers. Rigorous preclinical and clinical research efforts have yielded a diverse portfolio of late-stage product candidates focusing on the world’s most prevalent inflammatory conditions including osteoarthritis and diabetic macular edema. Significant discoveries in both basic science and clinical research have resulted in Ampio receiving over 180 patents throughout the world, with hundreds more pending. Further, hundreds of peer-reviewed publications, abstracts, and scientific presentations highlight the depth of research supporting Ampio’s therapeutic product candidates. Ampio’s leading product candidates are Ampion™ and Optina™. The company is currently conducting the second pivotal clinical trial in the US for Ampion, a biologic intra-articular injection being studied for the treatment of osteoarthritis of the knee. Ampio is also conducting a late-stage US clinical trial for Optina, an oral agent being studied for the treatment of diabetic macular edema. Millions of patients worldwide are affected by these conditions, for which limited treatment options exist. At Ampio, we strive to offer compelling therapeutic options for the patients most in need of new treatments, and we operate every day to advance our products’ development and make these available to patients.